Cargando…
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
BACKGROUND: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458830/ https://www.ncbi.nlm.nih.gov/pubmed/30975216 http://dx.doi.org/10.1186/s12967-019-1873-8 |
_version_ | 1783410093251887104 |
---|---|
author | Mahfoudh, Wijden Bettaieb, Inchirah Ghedira, Randa Snoussi, Kaouther Bouzid, Nadia Klayech, Zahra Gabbouj, Sallouha Remadi, Yassmine Hassen, Elham Bouaouina, Noureddine Zakhama, Abdelfateh |
author_facet | Mahfoudh, Wijden Bettaieb, Inchirah Ghedira, Randa Snoussi, Kaouther Bouzid, Nadia Klayech, Zahra Gabbouj, Sallouha Remadi, Yassmine Hassen, Elham Bouaouina, Noureddine Zakhama, Abdelfateh |
author_sort | Mahfoudh, Wijden |
collection | PubMed |
description | BACKGROUND: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. However, the contribution and the frequency of BRCA1 mutations in individuals with TNBC, not specifically selected for age at diagnosis or enriched family history of breast/ovarian cancer, have not been investigated in the Tunisian population and are to be established. The aim of the present study was to assess the contribution and the prevalence of recurrent BRCA1 germline mutation (5382inC) in Tunisian women with TNBC unselected for family history or age at onset. METHODS: For BRCA1 5382inC mutation detection, the exon 20 coding region and exon–intron boundaries of BRCA1 was analyzed using direct DNA sequencing. A total of 33 DNA samples from Tunisian women diagnosed with TNBC and unselected for family history or age at onset were analyzed. RESULTS: The 5382inC mutation was identified in 2 out of 33 women with TNBC with an overall prevalence of 6% (2/33). The detection rate of the 5382inC mutation among TNBC women with family history of breast cancer was 25% (2/8). The two 5382inC mutation carriers were postmenopausal and diagnosed at the age of 50 and 57. When stratified by age, the frequency of BRCA1 mutation in patients diagnosed at age ≥ 50 years was 8.7% (2/23). CONCLUSIONS: Our results confirm a noticeable contribution of BRCA1 5382inC mutation in TNBC development in Tunisia and further indicate that screening for 5382insC mutation in the BRCA1 gene is of interest in genetic testing in our population. Additionally, our data highlight that receptor triple negativity could be an effective selection criterion for BRCA1 genetic test in our population and should therefore be considered in genetic testing guidelines in Tunisia. |
format | Online Article Text |
id | pubmed-6458830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64588302019-04-22 Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia Mahfoudh, Wijden Bettaieb, Inchirah Ghedira, Randa Snoussi, Kaouther Bouzid, Nadia Klayech, Zahra Gabbouj, Sallouha Remadi, Yassmine Hassen, Elham Bouaouina, Noureddine Zakhama, Abdelfateh J Transl Med Research BACKGROUND: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. However, the contribution and the frequency of BRCA1 mutations in individuals with TNBC, not specifically selected for age at diagnosis or enriched family history of breast/ovarian cancer, have not been investigated in the Tunisian population and are to be established. The aim of the present study was to assess the contribution and the prevalence of recurrent BRCA1 germline mutation (5382inC) in Tunisian women with TNBC unselected for family history or age at onset. METHODS: For BRCA1 5382inC mutation detection, the exon 20 coding region and exon–intron boundaries of BRCA1 was analyzed using direct DNA sequencing. A total of 33 DNA samples from Tunisian women diagnosed with TNBC and unselected for family history or age at onset were analyzed. RESULTS: The 5382inC mutation was identified in 2 out of 33 women with TNBC with an overall prevalence of 6% (2/33). The detection rate of the 5382inC mutation among TNBC women with family history of breast cancer was 25% (2/8). The two 5382inC mutation carriers were postmenopausal and diagnosed at the age of 50 and 57. When stratified by age, the frequency of BRCA1 mutation in patients diagnosed at age ≥ 50 years was 8.7% (2/23). CONCLUSIONS: Our results confirm a noticeable contribution of BRCA1 5382inC mutation in TNBC development in Tunisia and further indicate that screening for 5382insC mutation in the BRCA1 gene is of interest in genetic testing in our population. Additionally, our data highlight that receptor triple negativity could be an effective selection criterion for BRCA1 genetic test in our population and should therefore be considered in genetic testing guidelines in Tunisia. BioMed Central 2019-04-11 /pmc/articles/PMC6458830/ /pubmed/30975216 http://dx.doi.org/10.1186/s12967-019-1873-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Mahfoudh, Wijden Bettaieb, Inchirah Ghedira, Randa Snoussi, Kaouther Bouzid, Nadia Klayech, Zahra Gabbouj, Sallouha Remadi, Yassmine Hassen, Elham Bouaouina, Noureddine Zakhama, Abdelfateh Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
title | Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
title_full | Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
title_fullStr | Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
title_full_unstemmed | Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
title_short | Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia |
title_sort | contribution of brca1 5382insc mutation in triple negative breast cancer in tunisia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458830/ https://www.ncbi.nlm.nih.gov/pubmed/30975216 http://dx.doi.org/10.1186/s12967-019-1873-8 |
work_keys_str_mv | AT mahfoudhwijden contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT bettaiebinchirah contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT ghediraranda contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT snoussikaouther contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT bouzidnadia contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT klayechzahra contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT gabboujsallouha contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT remadiyassmine contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT hassenelham contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT bouaouinanoureddine contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia AT zakhamaabdelfateh contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia |